Trial Search Results

Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I Disorder

The primary purpose of this study is to determine whether ELND005 is effective in the maintenance treatment of bipolar 1 disorder when added to other therapies.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Transition Therapeutics Ireland Limited

Collaborator: Elan Pharmaceuticals

Stanford Investigator(s):


  • Drug: ELND005
  • Drug: Lamotrigine
  • Drug: Valproic acid
  • Drug: Placebo


Phase 2


Inclusion Criteria:

   - Meets the DSM-IV-TR criteria for BPD I by the SCID, prior to the Screening Visit.

   - Has a history in the last 3 years of ≥ 1 manic or mixed episodes of sufficient
   severity that required hospitalization and/or treatment with a mood stabilizer or
   antipsychotic, or confirmed by a family member or medical records to ensure the
   episode fulfills the DSM-IV-TR criteria.

   - Has experienced a mood episode of any polarity within 4 months prior to the Screening
   Visit and responded to StOC therapy.

   - Is euthymic at the Screening Visit (ie, score of ≤ 12 on the MADRS and a score of ≤ 12
   on the Y-MRS).

   - Is receiving maintenance treatment for his or her BPD I with either LTG or VPA; on
   stable doses for past 4 weeks and therapeutic drug levels (total VPA 50--125 µg/mL and
   LTG 10-50 µmol/L or as deemed appropriate by the investigator). Dose adjustments made
   for tolerability reasons will be acceptable.

A study patient must meet the following additional criteria to be eligible for
randomization in the Double-blind Randomization Phase of this study:

- Maintained in a stable euthymic state during Phase 1, defined as Y-MRS and MADRS scores
of ≤ 12, with the following exceptions: a maximum of 2 nonconsecutive excursions will be
allowed throughout Phase 1. Excursions are defined as Y-MRS or MADRS scores >12 but ≤ 16.

Exclusion Criteria:

   - Woman of childbearing potential who is unwilling or unable to use an acceptable method
   of birth control or is using a prohibited contraceptive method.

   - Is found to be actively suicidal on the C-SSRS (answer of "yes" to question 4 or 5
   [current or over the last 30 days]) or a score of ≥4 on the MADRS item 10 at the
   Screening Visit.

   - Has suboptimally treated thyroid disease as evidenced by thyroid-stimulating hormone
   (TSH) >3 mIU/L at the Screening Visit.

   - Has received electroconvulsive therapy (ECT) during the current episode or within 6
   months prior to the Screening Visit.

   - Has an estimated glomerular filtration rate <40 mL/min/1.73 m2 according to the
   Modification of Diet in Renal Disease formula.

A study patient who meets ANY of the above and ANY of the criteria below will not be
eligible for enrollment in the Double-blind Randomization Phase of this study:

   - Has current signs or symptoms of psychosis.

   - Has become actively suicidal as defined by C-SSRS answer of "yes" to question 4 or 5
   (current or over the last 30 days) and/or has a score of ≥4 on MADRS item 10.

Ages Eligible for Study

18 Years - 65 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Shelley Hill
Not Recruiting